These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 23429601)

  • 1. Combination therapy for the treatment of neovascular age-related macular degeneration.
    Englander M; Kaiser PK
    Curr Opin Ophthalmol; 2013 May; 24(3):233-8. PubMed ID: 23429601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-VEGF Therapy for Neovascular AMD and Polypoidal Choroidal Vasculopathy.
    Cheung GCM; Lai TYY; Gomi F; Ruamviboonsuk P; Koh A; Lee WK
    Asia Pac J Ophthalmol (Phila); 2017; 6(6):527-534. PubMed ID: 28971633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degeneration.
    Broadhead GK; Hong T; Chang AA
    Acta Ophthalmol; 2014 Dec; 92(8):713-23. PubMed ID: 24925048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferred therapies for neovascular age-related macular degeneration.
    Lally DR; Gerstenblith AT; Regillo CD
    Curr Opin Ophthalmol; 2012 May; 23(3):182-8. PubMed ID: 22450218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration.
    Scott AW; Bressler SB
    Curr Opin Ophthalmol; 2013 May; 24(3):190-6. PubMed ID: 23492430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
    Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation therapy: age-related macular degeneration.
    Mendez CA; Ehlers JP
    Dev Ophthalmol; 2013; 52():75-84. PubMed ID: 23989128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
    Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
    Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining response to anti-VEGF therapies in neovascular AMD.
    Amoaku WM; Chakravarthy U; Gale R; Gavin M; Ghanchi F; Gibson J; Harding S; Johnston RL; Kelly SP; Lotery A; Mahmood S; Menon G; Sivaprasad S; Talks J; Tufail A; Yang Y
    Eye (Lond); 2015 Jun; 29(6):721-31. PubMed ID: 25882328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.
    Gomi F; Oshima Y; Mori R; Kano M; Saito M; Yamashita A; Iwata E; Maruko R;
    Retina; 2015 Aug; 35(8):1569-76. PubMed ID: 25830698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration.
    Krebs I; Vécsei Marlovits V; Bodenstorfer J; Glittenberg C; Ansari Shahrezaei S; Ristl R; Binder S
    Acta Ophthalmol; 2013 May; 91(3):e178-83. PubMed ID: 23241227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does laser still have a role in the management of retinal vascular and neovascular diseases?
    Shah AM; Bressler NM; Jampol LM
    Am J Ophthalmol; 2011 Sep; 152(3):332-339.e1. PubMed ID: 21742309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
    Bakri SJ; Couch SM; McCannel CA; Edwards AO
    Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Photodynamic therapy for polypoidal choroidal vasculopathy.
    Nowak-Sliwinska P; van den Bergh H; Sickenberg M; Koh AH
    Prog Retin Eye Res; 2013 Nov; 37():182-99. PubMed ID: 24140257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy.
    Cho M; Barbazetto IA; Freund KB
    Am J Ophthalmol; 2009 Jul; 148(1):70-8.e1. PubMed ID: 19403115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy.
    de Oliveira Dias JR; Rodrigues EB; Maia M; Magalhães O; Penha FM; Farah ME
    Br J Ophthalmol; 2011 Dec; 95(12):1631-7. PubMed ID: 21546514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review.
    Lanzetta P; Mitchell P; Wolf S; Veritti D
    Br J Ophthalmol; 2013 Dec; 97(12):1497-507. PubMed ID: 23929309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TREATMENT OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION WITH RANIBIZUMAB COMBINED WITH KETOROLAC EYEDROPS OR PHOTODYNAMIC THERAPY.
    Semeraro F; Russo A; Delcassi L; Romano MR; Rinaldi M; Chiosi F; Costagliola C
    Retina; 2015 Aug; 35(8):1547-54. PubMed ID: 25784358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 50 years or older: 1-year results of a prospective clinical study.
    Lim JY; Lee SY; Kim JG; Lee JY; Chung H; Yoon YH
    Acta Ophthalmol; 2012 Feb; 90(1):61-7. PubMed ID: 20337606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of combination therapies for neovascular age-related macular degeneration.
    Couch SM; Bakri SJ
    Semin Ophthalmol; 2011 May; 26(3):114-20. PubMed ID: 21609223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.